Rud, J.E., Chiu, D.S., Usui, M.L., Gibran, N.S. and Ansel, J.C. (1998) Protein gene solution 9.5 is expressed by fibroblasts in human cutaneous wounds. J. Invest. Dermatol. 111, 56572 CrossRef PubMed 20 Tezel, E., Hibi, K., Nagasaka, T. and Nakao, A. (2000) PGP9.5 as a prognostic factor in pancreatic cancer. Clin. Cancer Res. six, 4764767 PubMed 21 Yamazaki, T., Hibi, K., Takase, T., Tezel, E., Nakayama, H., Kasai, Y., Ito, K., Akiyama, S., Nagasaka, T. and Nakao, A. (2002) PGP9.five as a marker for invasive colorectal cancer. Clin. Cancer Res. 8, 19295 PubMed 22 Miyoshi, Y., Nakayama, S., Torikoshi, Y., Tanaka, S., Ishihara, H., Taguchi, T., Tamaki, Y. and Noguchi, S. (2006) High expression of ubiquitin carboxy-terminal hydrolase-L1 and -L3 mRNA predicts early recurrence in patients with invasive breast cancer. Cancer Sci. 97, 52329 CrossRef PubMed 23 Wilson, P.O., Barber, P.C., Hamid, Q.A., Power, B.F., Dhillon, A.P., Rode, J., Day, I.N., Thompson, R.J. and Polak, J.M. (1988) The immunolocalization of protein gene product 9.five using rabbit polyclonal and mouse monoclonal antibodies. Br. J. Exp. Pathol. 69, 9104 PubMed 24 Yasvoina, M.V., Genc, B., Jara, J.H., Sheets, P.L., Quinlan, K.A., Milosevic, A., Shepherd, G.M., Heckman, C.J. and Ozdinler, P.H. (2013) eGFP expression below UCHL1 promoter genetically labels corticospinal motor neurons and also a subpopulation of degeneration-resistant spinal motor neurons in an ALS mouse model. J. Neurosci. 33, 7890904 CrossRef PubMed 25 Liu, Y., Fallon, L., Lashuel, H.A., Liu, Z. and Lansbury, Jr, P.T. (2002) The UCH-L1 gene encodes two opposing enzymatic activities that impact alpha-synuclein degradation and Parkinson’s disease susceptibility. Cell 111, 20918 CrossRef PubMed 26 Takala, R.S., Posti, J.P., Runtti, H., Newcombe, V.2791273-76-0 site F., Outtrim, J., Katila, A.J., Frantzen, J., Ala-Seppala, H., Kyllonen, A., Maanpaa, H.R. et al. (2016) GFAP and UCH-L1 as outcome predictors in traumatic brain injury. World Neurosurg. 87, 80 CrossRef PubMed 27 Liu, Z., Meray, R.K., Grammatopoulos, T.N., Fredenburg, R.A., Cookson, M.R., Liu, Y., Logan, T. and Lansbury, Jr, P.T. (2009) Membrane-associated farnesylated UCH-L1 promotes alpha-synuclein neurotoxicity and is really a therapeutic target for Parkinson’s disease.352525-25-8 supplier Proc.PMID:24179643 Natl. Acad. Sci. U.S.A. 106, 4635640 CrossRef PubMed 28 Chen, J., Huang, R.Y. and Turko, I.V. (2013) Mass spectrometry assessment of ubiquitin carboxyl-terminal hydrolase L1 partitioning amongst soluble and particulate brain homogenate fractions. Anal. Chem. 85, 6011017 CrossRef PubMed 29 Bishop, P., Rubin, P., Thomson, A.R., Rocca, D. and Henley, J.M. (2014) The ubiquitin C-terminal hydrolase L1 (UCH-L1) C terminus plays a essential part in protein stability, but its farnesylation is just not expected for membrane association in key neurons. J. Biol. Chem. 289, 361406149 CrossRef PubMed 30 Sowa, M.E., Bennett, E.J., Gygi, S.P. and Harper, J.W. (2009) Defining the human deubiquitinating enzyme interaction landscape. Cell 138, 38903 CrossRef PubMedUCH-L1 and upkeep of axonal integrityUCH-L1 is necessary for the maintenance of axonal health and stability and its loss results in axonal degeneration and neuronal death. Even so, in spite of this clear and reproducible phenotype, as set about above, the mechanisms underlying this degeneration are unclear. We count on that future experiments exploring irrespective of whether the Cys90 mutation causes the identical axonal degeneration and ataxic phenotype because the Glu7Ala mutation in vivo will support resolv.
